Herpes Simplex Virus-2

DNA Technology Induces Immune Response Against HSV-2

Published in Gene Therapy Weekly, November 4th, 1996

Paradigm Biosciences, Inc., Salt Lake City, Utah, presented results of studies demonstrating that a nucleic acid vaccine using a novel non-viral promoter induces a vigorous immune response in mice to the Herpes Simplex virus II (HSV-2).

The response is further enhanced by the inclusion of a vitamin D3 adjuvant. The results were presented at IBC's 4th Annual International Conference on Mucosal Immunization, Genetic Approaches & Adjuvants, held in Washington, D.C., in October 1996.

"One of the major concerns raised regarding early nucleic acid delivery systems involved the use of non-specific viral promoters, which could activate systemic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1996-11-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry